FDG-PET–driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study-Reference-Cited by-同舟云学术

FDG-PET–driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study

Published:2017-09-14 Issue:11 Volume:130 Page:1315-1326
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Casasnovas R.-O.¹,Ysebaert L.²,Thieblemont C.³,Bachy E.⁴,Feugier P.⁵,Delmer A.⁶,Tricot S.⁷,Gabarre J.⁸,Andre M.⁹,Fruchart C.¹⁰,Mounier N.¹¹,Delarue R.¹²,Meignan M.¹³,Berriolo-Riedinger A.¹⁴,Bardet S.¹⁵,Emile J.-F.¹⁶¹⁷,Jais J.-P.¹⁸,Haioun C.¹⁹,Tilly H.²⁰,Morschhauser F.²¹

Affiliation:

1. Department of Hematology, Hôpital Le Bocage and INSERM Unité Mixte de Recherche1231, Dijon, France;

2. Department of Hematology, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France;

3. Department of Hematology, Assistance Publique–Hôpitaux de Paris (APHP), Hôpital Saint Louis, Université Paris Diderot-Sorbonne Paris-Cité, Paris, France;

4. Department of Hematology, Hôpital Lyon Sud, Pierre Bénite, France;

5. Department of Hematology, University Hospital of Nancy, Vandoeuvre les Nancy, France;

6. Department of Hematology, University Hospital of Reims, Reims, France;

7. Department of Hematology, Hospital of Valenciennes, Valenciennes, France;

8. Department of Hematology, Hôpital Pitié Salpetrière, Paris, France;

9. Department of Hematology, Centre Hospitalier Universitaire, Université Catholique de Louvain Namur, Université Catholique de Louvain, Yvoir, Belgium;

10. Department of Hematology, Institut d’hématologie de Basse Normandie, Caen, France;

11. Department of Hematology, University Hospital of Nice, Nice, France;

12. Department of Hematology, Hôpital Necker, Paris, France;

13. Department of Nuclear Medicine, Hôpital H. Mondor, Creteil, France;

14. Department of Nuclear Medicine, Centre G. F. Leclerc, Dijon, France;

15. Department of Nuclear Medicine, Centre F. Baclesse, Caen, France;

16. Department of Pathology, APHP, Hôpital Ambroise-Paré, Boulogne, France;

17. Department of Pathology, EA430 Université de Versailles, Versailles, France;

18. Department of Biostatistics, Hôpital Necker, Paris, France;

19. Department of Hematology, Hôpital H. Mondor, Creteil, France;

20. Department of Hematology, Centre H. Becquerel, Rouen, France; and

21. Department of Hematology, Hôpital Claude Huriez, Université Lille, EA 7365, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France

Abstract

Key Points Superiority of R-ACVBP over R-CHOP14 was not established, as IHP criteria driving consolidation did not properly reflect disease control. The 26% PET2−/PET4− patients using IHP criteria increased to 79% using ΔSUVmax, which may help better select those needing an alternative to SIC.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/11/1315/1402358/blood766691.pdf

Reference26 articles.

1. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis;Greb;Cancer Treat Rev,2007

2. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Tilly;Ann Oncol,2015

3. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1);Schmitz;Lancet Oncol,2012

4. Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas;Cortelazzo;J Clin Oncol,2016

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ROBI: a Robust and Optimized Biomarker Identifier to increase the likelihood of discovering relevant radiomic features;2024-09-10

2. International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline¹⁸F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation;Journal of Nuclear Medicine;2024-08-01

3. Evaluating Outcome Prediction via Baseline, End-of-Treatment, and Delta Radiomics on PET-CT Images of Primary Mediastinal Large B-Cell Lymphoma;Cancers;2024-03-08

4. Значение ПЭТ, совмещенной с КТ, при диффузной В-крупноклеточной лимфоме: история вопроса, эволюция представлений и современные возможности метода (обзор литературы);Clinical Oncohematology;2024-02-20

5. NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL;Leukemia & Lymphoma;2024-02-09